c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis

Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma

(2020) Motoo Nomura et al.   International Journal of Clinical Oncology

CheckMate 067: Long-term outcomes in patients with mucosal melanoma.

(2020) Alexander Noor Shoushtari et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

(2020) Felicity Newell et al.   Nature Communications

Melanoma on Chronically Sun Damaged Skin: Lentigo Maligna and Desmoplastic Melanoma

(2019) Madeline E. DeWane et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development

(2019) Da Meng et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

(2019) Felicity Newell et al.   Nature Communications

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

(2019) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma: What do all the mutations mean?

(2018) Elizabeth J. Davis et al.   CANCER

Diagnosis and Management of Acral Lentiginous Melanoma

(2018) Yoshiyuki Nakamura et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

(2018) Julie Delyon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mucosal Melanoma: a Literature Review

(2018) Simon Skovsted Yde et al.   Current Oncology Reports

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

(2018) Omid Hamid et al.   BRITISH JOURNAL OF CANCER

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

(2017) Sandra P. D’Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

(2015) Elizabeth I. Buchbinder et al.   CANCER

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

(2015) R. D. Carvajal et al.   CLINICAL CANCER RESEARCH

Driver KIT mutations in melanoma cluster in four hotspots

(2015) Nicolas Dumaz et al.   MELANOMA RESEARCH

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

(2015) S. J. Lee et al.   ONCOLOGIST

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

(2013) A Adenis et al.   BRITISH JOURNAL OF CANCER

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

(2013) Michele Del Vecchio et al.   EUROPEAN JOURNAL OF CANCER

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

(2013) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab for Patients With Advanced Mucosal Melanoma

(2013) M. A. Postow et al.   ONCOLOGIST

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

(2011) Jin Hyun Cho et al.   INVESTIGATIONAL NEW DRUGS

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER